C4 Therapeutics Files 8-K, Material Agreement Details
Ticker: CCCC · Form: 8-K · Filed: Apr 9, 2026 · CIK: 0001662579
| Field | Detail |
|---|---|
| Company | C4 Therapeutics, Inc. (CCCC) |
| Form Type | 8-K |
| Filed Date | Apr 9, 2026 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-update
TL;DR
C4Tx filed an 8-K for a material agreement - check the exhibits for deets.
AI Summary
On April 9, 2026, C4 Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement. The filing includes exhibits such as a corporate deck, indicating potential business developments or updates. Specific financial figures or counterparty names were not detailed in the provided filing summary.
Why It Matters
This filing signals a significant business development for C4 Therapeutics, potentially involving new partnerships, acquisitions, or strategic shifts that could impact its future operations and stock performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications, but the lack of specific details in the summary necessitates a medium risk assessment.
Key Players & Entities
- C4 Therapeutics, Inc. (company) — Filer of the 8-K report
- 0001628280-26-024336 (other) — SEC Accession Number for the filing
- 2026-04-09 (date) — Filing Date and Period of Report
FAQ
What is the nature of the material definitive agreement filed by C4 Therapeutics?
The filing indicates Item 1.01: Entry into a Material Definitive Agreement, but the specific details of the agreement are not provided in the summary.
What information is contained in the exhibits attached to the 8-K filing?
The exhibits include an iXBRL 8-K, EX-99.1, and a corporate deck (EX-99.2) along with several graphic files, suggesting business or financial updates.
When was this 8-K filing accepted by the SEC?
The filing was accepted on 2026-04-09 at 07:07:35.
What are the main items disclosed in this 8-K filing?
The main items disclosed are Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits).
Does the filing provide specific financial figures related to the material agreement?
The provided summary of the 8-K filing does not contain specific financial figures related to the material agreement.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 9, 2026 regarding C4 Therapeutics, Inc. (CCCC).